These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18593723)

  • 1. Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
    Moltó J; Valle M; Miranda C; Cedeño S; Miranda J; Santos JR; Negredo E; Vilaró J; Costa J; Clotet B
    J Antimicrob Chemother; 2008 Oct; 62(4):784-92. PubMed ID: 18593723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Lange JM; Danner SA; Foudraine NA; Kwakkelstein MO; Reiss P; Beijnen JH; Hoetelmans RM
    AIDS; 2000 May; 14(8):F77-82. PubMed ID: 10853971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
    Schipani A; Wyen C; Mahungu T; Hendra H; Egan D; Siccardi M; Davies G; Khoo S; Fätkenheuer G; Youle M; Rockstroh J; Brockmeyer NH; Johnson MA; Owen A; Back DJ;
    J Antimicrob Chemother; 2011 Jun; 66(6):1332-9. PubMed ID: 21441248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
    de Maat MM; Huitema AD; Mulder JW; Meenhorst PL; van Gorp EC; Beijnen JH
    Br J Clin Pharmacol; 2002 Oct; 54(4):378-85. PubMed ID: 12392585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
    Kappelhoff BS; Huitema AD; van Leth F; Robinson PA; MacGregor TR; Lange JM; Beijnen JH;
    HIV Clin Trials; 2005; 6(5):254-61. PubMed ID: 16306032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of nevirapine in Thai HIV-infected patients.
    Wattanakul T; Avihingsanon A; Manosuthi W; Punyawudho B
    Antivir Ther; 2014; 19(7):651-60. PubMed ID: 24504545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.
    Moltó J; Barbanoj MJ; Miranda C; Blanco A; Santos JR; Negredo E; Costa J; Domingo P; Clotet B; Valle M
    Clin Pharmacokinet; 2008; 47(10):681-92. PubMed ID: 18783298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.
    Mustafa S; Yusuf WN; Woillard JB; Choon TS; Hassan NB
    Eur J Clin Pharmacol; 2016 Jul; 72(7):831-8. PubMed ID: 27025609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
    Dickinson L; Boffito M; Back D; Waters L; Else L; Davies G; Khoo S; Pozniak A; Aarons L
    J Antimicrob Chemother; 2009 Jun; 63(6):1233-43. PubMed ID: 19329800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.
    Dickinson L; Boffito M; Back DJ; Khoo SH; Pozniak AL; Mugyenyi P; Merry C; Autar RS; Burger DM; Aarons LJ
    J Antimicrob Chemother; 2008 Dec; 62(6):1344-55. PubMed ID: 18824460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
    Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
    Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach.
    Dailly E; Raffi F; Perré P; Martin J; Deslandes G; Jolliet P
    HIV Med; 2009 Oct; 10(9):586-9. PubMed ID: 19486187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    Zhou XJ; Sheiner LB; D'Aquila RT; Hughes MD; Hirsch MS; Fischl MA; Johnson VA; Myers M; Sommadossi JP
    Antimicrob Agents Chemother; 1999 Jan; 43(1):121-8. PubMed ID: 9869576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.
    Svensson E; van der Walt JS; Barnes KI; Cohen K; Kredo T; Huitema A; Nachega JB; Karlsson MO; Denti P
    Br J Clin Pharmacol; 2012 Sep; 74(3):465-76. PubMed ID: 22300396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.
    Yong CL; Gathe JC; Knecht G; Orrell C; Mallolas J; Podzamczer D; Trottier B; Zhang W; Sabo JP; Vinisko R; Drulak M; Quinson AM
    HIV Clin Trials; 2017; 18(5-6):189-195. PubMed ID: 29210627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
    Néant N; Gattacceca F; Lê MP; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
    Eur J Clin Pharmacol; 2018 Apr; 74(4):473-481. PubMed ID: 29374296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of nevirapine dosing recommendations in HIV-infected children.
    Foissac F; Bouazza N; Frange P; Blanche S; Faye A; Lachassinne E; Dollfus C; Hirt D; Benaboud S; Treluyer JM; Urien S
    Br J Clin Pharmacol; 2013 Jul; 76(1):137-44. PubMed ID: 23278548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1.
    Dailly E; Allavena C; Grégoire M; Reliquet V; Bouquié R; Billaud E; Hernando H; Bouchez S; Deslandes G; Hall N; Jolliet P; Raffi F
    J Antimicrob Chemother; 2015 Dec; 70(12):3307-10. PubMed ID: 26271944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
    Elsherbiny D; Cohen K; Jansson B; Smith P; McIlleron H; Simonsson US
    Eur J Clin Pharmacol; 2009 Jan; 65(1):71-80. PubMed ID: 18751690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.